Zimmer Biomet Holdings, Inc. (ZBH) Free Cash Flow CAGR:36.08%(TTM)
Free cash flow CAGR uses precomputed cash-flow statement history.
Over longer horizons, Zimmer Biomet Holdings, Inc.'s Free Cash Flow CAGR averages 17.10% over 3 years and 15.41% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Free cash flow CAGR measures how Zimmer Biomet Holdings, Inc.'s cash generation has grown. FCF represents the cash available for dividends, buybacks, debt reduction, or reinvestment.
ZBH Free Cash Flow CAGR Chart
Zimmer Biomet Holdings, Inc. (ZBH)
ZBH Quarterly Free Cash Flow Growth (YoY)
Free Cash Flow growth vs the same quarter one year earlier, last 20 quarters.
ZBH Free Cash Flow CAGR History
| Year | Start FCF | End FCF | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $1.14B | $1.47B | +$329.90M | +28.87% | +28.87% |
| 2024 | $1.19B | $1.14B | $-44.50M | -3.75% | -3.75% |
| 2023 | $1.07B | $1.19B | +$120.00M | +11.25% | +11.25% |
| 2022 | $1.35B | $1.07B | $-280.10M | -20.79% | -20.79% |
| 2021 | $1.09B | $1.35B | +$254.60M | +23.30% | +23.30% |
| 2020 | $1.18B | $1.09B | $-88.50M | -7.49% | -7.49% |
| 2019 | $1.58B | $1.18B | $-403.60M | -25.47% | -25.47% |
| 2018 | $1.43B | $1.58B | +$158.40M | +11.11% | +11.11% |
| 2017 | $1.45B | $1.43B | $-21.20M | -1.46% | -1.46% |
| 2016 | $682.10M | $1.45B | +$765.40M | +112.21% | +112.21% |
| 2015 | $915.60M | $682.10M | $-233.50M | -25.50% | -25.50% |
| 2014 | $863.10M | $915.60M | +$52.50M | +6.08% | +6.08% |
| 2013 | $1.04B | $863.10M | $-174.10M | -16.79% | -16.79% |
| 2012 | $1.06B | $1.04B | $-25.90M | -2.44% | -2.44% |
| 2011 | $1.11B | $1.06B | $-42.70M | -3.86% | -3.86% |
| 2010 | $852.90M | $1.11B | +$252.90M | +29.65% | +29.65% |
| 2009 | $440.80M | $852.90M | +$412.10M | +93.49% | +93.49% |
| 2008 | $753.20M | $440.80M | $-312.40M | -41.48% | -41.48% |
| 2007 | $772.40M | $753.20M | $-19.20M | -2.49% | -2.49% |
| 2006 | $772.90M | $772.40M | $-500.00K | -0.06% | -0.06% |
| 2005 | $761.40M | $772.90M | +$11.50M | +1.51% | +1.51% |
| 2004 | $336.30M | $761.40M | +$425.10M | +126.40% | +126.40% |
| 2003 | $186.50M | $336.30M | +$149.80M | +80.32% | +80.32% |
| 2002 | $117.10M | $186.50M | +$69.40M | +59.27% | +59.27% |
| 2001 | $203.40M | $117.10M | $-86.30M | -42.43% | -42.43% |
| 2000 | $147.00M | $203.40M | +$56.40M | +38.37% | +38.37% |
| 1999 | $179.00M | $147.00M | $-32.00M | -17.88% | -17.88% |
Quarterly Free Cash Flow: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $322.90M | -51.7% | -3.8% |
| Q4 2025 | $668.70M | +22.5% | +58.7% |
| Q3 2025 | $545.80M | +83.1% | +48.1% |
| Q2 2025 | $298.10M | -11.2% | +33.7% |
| Q1 2025 | $335.80M | -20.3% | +159.1% |
| Q4 2024 | $421.40M | +14.3% | -19.8% |
| Q3 2024 | $368.60M | +65.3% | +66.6% |
| Q2 2024 | $223.00M | +72.1% | +12.5% |
| Q1 2024 | $129.60M | -75.3% | -47.5% |
| Q4 2023 | $525.60M | +137.6% | +190.7% |
| Q3 2023 | $221.20M | +11.5% | -45.2% |
| Q2 2023 | $198.30M | -19.7% | -36.4% |
| Q1 2023 | $247.00M | +36.6% | +23.0% |
| Q4 2022 | $180.80M | -55.2% | -26.5% |
| Q3 2022 | $403.60M | +29.5% | +3.7% |
| Q2 2022 | $311.60M | +55.2% | -15.4% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Zimmer Biomet Holdings, Inc.
Zimmer Biomet Holdings, Inc. (ZBH), along with its global subsidiaries, operates as a leading player in the musculoskeletal healthcare sector. The company extends its reach across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. ZBH is responsible for the design, manufacturing, and marketing of a wide array of orthopedic reconstructive solutions, including prominent knee and hip replacement systems. Their offerings also encompass Specialized Enabling Technologies (S.E.T.) products, which cover areas such as sports medicine, biologics, foot and ankle care, extremity treatments, and trauma management. Furthermore, the company provides medical devices and surgical instruments specifically for spinal conditions, alongside products for facial and cranial reconstruction. A unique part of their portfolio includes systems designed to stabilize and fixate chest bones, facilitating recovery or reconstruction following open-heart surgery, traumatic injuries, or congenital chest deformities. The company's product lines also feature a comprehensive range of dental solutions, such as reconstructive implants, prosthetics, and regenerative materials. Additionally, they are involved in robotic surgical systems, general surgical instruments, and bone cements. These advanced products and solutions are primarily utilized to address conditions in patients suffering from disorders or injuries affecting bones, joints, and their associated soft tissues. Zimmer Biomet caters to a broad clientele, including orthopedic, neuro-, and oral surgeons, dentists, hospitals, independent distributors, healthcare suppliers, and various other medical specialists. Their network further encompasses agents, healthcare purchasing organizations, and group buying alliances. Originally established in 1927, the enterprise was initially known as Zimmer Holdings, Inc., before rebranding as Zimmer Biomet Holdings, Inc. in June 2015. Its corporate headquarters are situated in Warsaw, Indiana.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ivan Tornos